Case-control study of the α-synuclein interacting protein gene and Parkinson's disease

Movement Disorders

Volumn 18, Issue 11, 2003, Pages 1233-1239

  Maraganore, Demetrius M ^a   Farrer, Matthew J ^b   Lesnick, Timothy G ^a   de Andrade, Mariza ^a   Bower, James H ^a   Hernandez, Dena ^c   Hardy, John A ^c   Rocca, Walter A ^a  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Alpha synuclein; Association; Interactions; Parkin; Parkinson's disease; Susceptibility genes; Synphilin 1

Indexed keywords

ALPHA SYNUCLEIN; GENE PRODUCT; MICROSATELLITE DNA; PARKIN; SYNPHILIN 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CHROMOSOME 5Q; CHROMOSOME MAP; CONTROLLED STUDY; EXON; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN INTERACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCORING SYSTEM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; CARRIER PROTEINS; CASE-CONTROL STUDIES; CHROMOSOMES, HUMAN, PAIR 5; EXONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTRONS; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; NERVE TISSUE PROTEINS; PARKINSON DISEASE; POINT MUTATION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SINGLE-BLIND METHOD; SYNUCLEINS; UBIQUITIN-PROTEIN LIGASES;

EID: 1342347424     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10547     Document Type: Article

References (37)

1. Engelender S, Wanner T, Kleiderlein JJ, et al. Organization of the human synphilin-1 gene, a candidate for Parkinson's disease. Mamm Genome 2000;11:763-766.
2. O'Farrell C, Pickford F, Vink L, et al. Sequence conservation between mouse and human synphilin-1. Neurosci Lett 2002;322:9-12.
3. Engelender S, Kaminsky Z, Guo X, et al. Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat Genet 1999;22:110-114.
4. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.
5. Krüger R, Kuhn W, Müller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998; 18:106-108.
6. Krüger R, Vieira-Saecker AM, Kuhn W, et al. Increased susceptibility to sporadic Parkinson's disease by a certain combined alpha-synuclein/apolipoprotein E genotype. Ann Neurol 1999;45: 611-617.
7. Farrer M, Maraganore DM, Lockhart P, et al. Alpha-synuclein gene haplotypes are associated with Parkinson's disease. Hum Mol Genet 2001;10:1847-1851.
8. Neystat M, Rzhetskaya M, Kholodilov N, Burke RE. Analysis of synphilin-1 and synuclein interactions by yeast two-hybrid beta-galactosidase liquid assay. Neurosci Lett 2002;325:119-123.
9. O'Farrell C, Murphy DD, Petrucelli L, et al. Transfected synphilin-1 forms cytoplasmic inclusions in HEK293 cells. Brain Res Mol Brain Res 2001:97:94-102.
10. Ribeiro CS, Carneiro K, Ross CA, et al. Synphilin-1 is developmentally localized to synaptic terminals and its association with synaptic vesicles is modulated by α-synuclein. J Biol Chem 2002; 277:23927-23933.
11. Lücking CB, Dürr A, Bonifati V, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 2000;342:1560-1567.
12. West AB, Maraganore D, Crook J, et al. Functional association of the parkin gene promoter with idiopathic Parkinson's disease. Hum Mol Genet 2002;11:2787-2792.
13. Chung KK, Zhang Y, Lim KL, et al. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat Med 2001;7: 1144-1150.
14. Wakabayashi K, Engelender S, Yoshimoto M, et al. Synphilin-1 is present in Lewy bodies in Parkinson's disease. Ann Neurol 2000; 47:521-523.
15. Wakabayashi K, Engelender S, Tanaka Y, et al. Immunocytochemical localization of synphilin-1, an alpha-synuclein-associated protein, in neurodegenerative disorders. Acta Neuropathol 2002;103: 209-214.
16. Scott WK, Nance MA, Watts RL, et al. Complete genomic screen in Parkinson's disease: evidence for multiple genes. JAMA 2001; 286:2239-2244.
17. Hicks AA, Pétursson H, Jónsson T, et al. A susceptibility gene for late-onset idiopathic Parkinson's disease. Ann Neurol 2002;52: 549-555.
18. Pankratz N, Nichols WC, Uniacke SK, et al. Genome screen to identify susceptibility genes for Parkinson's disease in a sample without parkin mutations. Am J Hum Genet 2002;71:124-135.
19. Maraganore DM, Farrer MJ, Hardy JA, Lincoln SJ, McDonnell SK, Rocca WA. Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology 1999;53:1858-1860.
20. Maraganore DM, Farrer MJ, Hardy JA, McDonnell SK, Schaid DJ, Rocca WA. Case-control study of debrisoquine 4-hydroxylase, N-acetyltransferase 2, and apolipoprotein E gene polymorphisms in Parkinson's disease. Mov Disord 2000;15:714-719.
21. Maraganore DM, Hernandez DG, Singleton AB, et al. Case-control study of the extended tau gene haplotype in Parkinson's disease. Ann Neurol 2001;50:658-661.
22. Maraganore DM, Farrer MJ, McDonnell SK, et al. Case-control study of estrogen receptor gene polymorphisms in Parkinson's disease. Mov Disord 2002;17:509-512.
23. Goudreau JL, Maraganore DM, Farrer MJ, et al. Case-control study of dopamine transporter-1, monoamine oxidase-B, and catechol-O-methyl transferase polymorphisms in Parkinson's disease. Mov Disord 2002;17:1305-1311.
24. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 1999;52:1214-1220.
25. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Influence of strict, intermediate, and broad diagnostic criteria on the age- and sex-specific incidence of Parkinson's disease. Mov Disord 2000; 15:819-825.
26. Farrer M, Destée A, Levecque C, et al. Genetic analysis of synphilin-1 in familial Parkinson's disease. Neurobiol Dis 2001;8:317-323.
27. Breslow NE, Day NE. Statistical methods in cancer research. Volume I. The analysis of case-control studies. IARC Sci Publ 1980;32:5-338.
28. Knowler WC, Williams RC, Pettitt DJ, Steinberg AG. Gm3;5,13,14 and type 2 diabetes mellitus: an association in American Indians with genetic admixture. Am J Hum Genet 1988;43:520-526.
29. Schaid DJ, Rowland CM, Tines DE, et al. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002;70:425-434.
30. Weir BS. Genetic data analysis II. Sunderland, MA: Sinauer Associates, Inc.; 1996.
31. Zhang H, Bonney G. Use of classification trees for association studies. Genet Epidemiol 2000;19:323-332.
32. Maraganore DM, de Andrade M, Lesnick TG, et al. Complex interactions in Parkinson's disease: a two-phased approach. Mov Disord 2003;18:631-636.
33. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th Ed. DSM-IV. Washington, DC: American Psychiatric Association; 1994.
34. Bandopadhyay R, de Silva R, Khan N, et al. No pathogenic mutations in the synphilin-1 gene in Parkinson's disease. Neurosci Lett 2001;307:125-127.
35. Satoh J-I, Kuroda Y. A putative polymorphic Val44Ala variation in the synphilin-1 gene is undetectable in Japanese sporadic Parkinson's disease patients. Eur J Neurol 2002;9:15-18.
36. Thornton A, Lee P. Publication bias in meta-analysis: its causes and consequences. J Clin Epidemiol 2000;53:207-216.
37. Tefferi A, Wieben ED, Dewald GW, Whiteman DAH, Bernard ME, Spelsberg TC. Primer on medical genomics. Part II: background principles and methods in molecular genetics. Mayo Clin Proc 2002;77:785-808.